The Big Pharma Companies Have A Number Of Responsibilities

This paper hopes to share insight into the steps that are taken by companies, and the strenuous process behind developing an effective new drug.

U.S. based companies hold rights to most of the world’s rights on new medicines and holds thousands of new products currently being developed. As of 2012, the industry helps support almost 3.4 million jobs in the U.S. economy. It is also one of the most heavily R&D based industries in the world. In the United States, the environment for pharmaceuticals is much friendlier than other countries around the world in terms of pricing ability and regulations. Both the Pharmaceutical and Biotechnology industries have experienced significant growth in the past year with year-over-year increases of 13.02% and 34.69% respectively. It is an even more striking when looking at the past five years considering both have beat out the S&P 500 with pharmaceuticals increasing an additional 31.44% and the biotechnology sector besting an astonishing 269.3% more return than the

One primary goal of Pfizer is to deliver sustained, excellent product by outperforming Pfizer’s competitors and must differentiate itself adequately from its competitors. Competitive advantage is central to strategic management in that it will produce and sustain superior performance. To be competitive in a business environment, often it requires the company to have a product or service different and better than other organizations competing in the same marketplace. According to Wadman (2007) “Pfizer and the rest of the pharmaceutical industry need to develop more sophisticated drugs, targeted at a smaller number of people more quickly, efficiently and at a lower cost” (p. 1). Once Pfizer’s strengths, weaknesses, opportunities, and threats are assessed and analyzed, managers must decide a set of strategies to reduce or eliminate its weaknesses and capitalize on its strengths and maximize opportunities. An example is Porter’s three generic strategy approaches of differentiation, cost leadership, and focus strategy by using differentiation strategies to differentiate Pfizer from its competitors. Strategies are essential; however, it is useless unless they are effectively implemented levels of the company. Business-level strategies are typically developed and implemented by heads of business units and are first approved by top management. The functional level strategy is the last level that focuses on developing strategies for managing the various departments to

Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well

Pharmaceutical companies also show a key role in the healthcare system because many patients trust their products. The values for drugs are increasing, and there are no covers to

Joseph Dumit announces how pharmaceutical organizations are exploiting us shoppers, control with showcasing procedures and making it so we return for more solution. These brings up the issue do pharmaceuticals have our best enthusiasm to make us more beneficial or are they just in it for the cash. Dumit states that in 2011 pharmaceuticals made about $880 billion dollars and is relied upon to grow 5% consistently later on (18). Dumit thinks something is wrong with these organizations and takes a gander at the ceaseless development in medications, conclusion, expenses and weakness, he adopted the strategy to take after cash and following associations between the benefits of organizations and ailment extension (10).

Biopharmaceutical companies are known for their innovative discoveries but they will need to be known for their innovative business strategies to survive the Affordable Care Act. The reality of the Affordable Care Act is that physicians no longer control treatment decisions. The Affordable Care Act has been responsible for health care consolidation. Hospital mergers and hospital system formations have increased and the employment of physicians by these organizations has increased. With consolidation, the power of patient treatment has shifted from physicians to management and administration. Treatment decisions that were made by physicians are now being institutionalized. Hospital administrators, pharmacy benefit managers and insurance companies now control patient treatment decisions. Biopharmaceutical companies must understand what clinical and economic data management and administration value. There is increased focus on cost

When an established multinational pharmaceutical company shows signs of early trouble, the sales and net revenue are falling, stock value is heading southwards and there is

Technological Change refers to the emergence of new products and processes in the marketplace brought about by innovative initiatives and distributive strategies; this in turn motivates formation of new industries and competitive rivalries for the organization. At Bayer it has always been their mission to create new innovations to better the lives of people. The pharmaceutical company has focused over the years on health care, nutrition and high-tech materials. Through Bayer Schering Pharma AG in Germany the company has been spearheading R&D in Oncology by employing multiple strategies and decimating competitive influences in the process. By analyzing Bayer’s competitive approach to R & D, we can better grasp the scope of

GSK is the 2nd largest pharmaceutical firm in the world, and the largest in the UK by sales and profits, it is responsible for 7% of the worlds pharmaceutical market, and has its stocks listed both in UK and US (O 'Rourke, 2002). The origin of the so called blockbuster model, is partly linked with Glaxo (as it was previously known). In the early 80’s, then Glaxo brought to light their first blockbuster drug, Zantac, which was an anti-ulcer drug, which was very similar to the a pre existing drug Tagamet (first ever blockbuster) sold by Smith Kline & French, their completion at the time (MONTALBAN and SAKINÇ, 2011). The introduction of this drug, brought about an increasing sales force in the US, the company soon became dependent on the drug, because it represented a large part of their profit. In 2002, 8 blockbusters of GSK contributed to $14.240 million sales revenue, taking up 53% of its total ethical sales (Froud et al 2006). However, due to the nature of the pharmaceutical industry, the patent began to expire, in other to avoid the patent cliff, Glaxo merged with Wellcome in 1995, which ensured a growing number of sales force, and with Beecham in 2000 (Froud et al., 2006) this merger, boosted the confidence of investors, by growing the business inorganically. For Big Pharma, this block buster model is very profitable, because with the high cost of R&D, the drugs are able to generate ample profit, to cover the sunk costs

The research and development of the pharmaceutical industry is very important as the industry relies on it to develop new products to maintain and sustain the growth of the industry (ALRC 2014). According to the Australian Government Law Reform Commission, every year, the total spending in research and development in pharmaceutical industry, which includes drug discovery, pre-clinical testing and clinical trials on drugs is around $300 million (ALRC 2014). Mergers and acquisitions are intensifying in the global pharmaceutical industry, especially over the last 10 years. With factors like exorbitant research and development costs, the relatively shorter product life cycles, and the rarity of discovering a new life-changing drug acting as catalysts, leading pharmaceutical companies now have more cause to step out and look for external collaboration. This results in an increasing number of smaller biotechnology companies merging with bigger pharmaceutical companies (The

To understand the competitive landscape of the industry in which one is competing, it must understand how to formulate strategies that will create a profitable business. A business must know what it is good at to be able to effectively have a competitive advantage over other businesses within that industry. The profitability of Mylan Pharmaceuticals largely depends on their ability to discover and market new drugs. The desire to cure illness and disease is what demands pharmaceutical companies like Mylan to be empowered to do their very best. Companies like Mylan Pharmaceuticals, profit from their economies of scale in research, manufacturing, and marketing. A competitive strategy analysis will show why Mylan Pharmaceuticals is one of the leading generic and specialty drug manufacturing companies in the world.

Although R&D has been retained by the large pharmaceutical firms, there has been a continuous decline in the R&D productivity. Controlling R&D is imperative to the success of a Pharmaceutical firm. However, as the pharmaceutical industry is maturing, there are diminishing returns to the R&D investment. Fewer and fewer blockbuster drugs are being discovered and therefore R&D is not the most value adding component in the value

This is a strategic analysis of GlaxoSmithKline that examines the key factors that influence the company and its activities. The strategic analysis will examine key factors in the company’s internal and external environment and their influence on the company’s strategies. GlaxoSmithKline is a global healthcare company that offers pharmaceutical, vaccines and consumer products. The company is a product of various mergers, the latest occurring in 2001 between GlaxoWellcome and SmithKline Beecham. The company started in London United Kingdom in 1715 as Plough Court pharmacy and has evolved to become one of the leading global healthcare companies. The healthcare company operates in more than 150 countries with 89 manufacturing locations and research centers in the USA, China, UK and Belgium. In 2015, the company’s sales grew to £23.9 billion from £23.0 billion in 2014 (GlaxoSmithKline plc. 2015).

The decisions that the companies make are affected by the problem of resource scarcity. With many opportunities but limited resources, the companies should know what is the best to invest their cash in. Always, there is the question of how and where to invest the cash, it is a real challenge for those who are responsible for allocating the resources. Pharmaceutical companies may have 10, 30 or 100 products should be managed. These products differ in potential growth, competitive environment, and performance. The decision is very hard to choose which products that the company should invest. The BCG matrix or GE compare the products and divide them to the groups that are worth investing in or the groups that should be harvested or divested. The purpose of these tools is highlighting growth potential, relative market share, and cash flow potential between different products in portfolio. These differences can indicate which products that can generate investment funds and which Should, perhaps, be discontinued